| GTO ID | GTC3417 |
| Trial ID | NCT05827978 |
| Disease | Seasonal Influenza |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1010 |
| Phase | Phase3 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 3, Randomized, Stratified, Observer-Blind, Active-Controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of mRNA-1010 Seasonal Influenza Vaccine in Adults 18 Years and Older |
| Year | 2023 |
| Country | United States |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-1010-P303 |
| Vector information | |||
|
|||
| Cohort1: mRNA-1010 | |||||||
|
|||||||
| Cohort2: Fluarix Quadrivalent | |||||||
|
|||||||